Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial

NEXT STORY
First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis
PREV STORY
Neuronetics Launches Upgrades of NeuroStar® Advanced Therapy for Mental Health
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The Global Human Microbiome Modulators Market – Forecast to 2023: Projected to Reach $2.79 Billion

Dublin, Dec. 13, 2018 (GLOBE NEWSWIRE) -- The "Global Human Microbiome Modulators Market: Focus ...

author_avatar
NASDAQ Market News

Kalytera Announces Formation of Strategic and Scientific Advisory Board to Assist with Development of Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

SAN FRANCISCO and TEL AVIV, Israel, May 15, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, ...

author_avatar
NASDAQ Market News

MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China

Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing developmentExpand Zai ...

author_avatar
NASDAQ Market News